1. Breast cancer in men: A 10-year experience of an oncology reference center in Northeast Mexico.
- Author
-
SALAZAR-MEJÍA, CARLOS EDUARDO, BURGUETE-TORRES, ALAN, GONZÁLEZ-GUERRERO, JUAN FRANCISCO, GALLEGOS-ARGUIJO, DANIEL ALBE RTO, R-CASTILLO, BLANCA OTILIA WIME, SAMANIEGO-SÁENZ, BRENDA ALEJANDRA, CHAPA-MONTALVO, LOURDES PAOLA, and VIDAL-GUTIÉRREZ, OSCAR
- Subjects
- *
EPIDERMAL growth factor receptors , *BREAST cancer , *CANCER in men , *LUMPECTOMY , *HORMONE receptors - Abstract
Introduction: Breast cancer in men (BCM) accounts for approximately 1% of all breast cancer cases. The present study aimed at describing the clinical and demographic characteristics of BCM in Mexican population. Methods: We performed a retrospective analysis of the men with newly diagnosed breast cancer treated in an oncology referral center in Northeast Mexico from 2007 to 2017. Results: Fifteen patients were included in the analysis. Mean age at diagnosis was 60.7 years and median time from diagnosis to the start of treatment was 2 months. About 73% of patients presented with locoregional disease (clinical stage [CS] I-III) and 26.7% were classified as Stage IV disease on their first assessment. All patients had invasive ductal carcinoma and 60.0% were Grade II tumors. Twelve cases were positive for hormone receptors and none showed overexpression of human epidermal growth factor receptor 2. Regarding primary treatment, 12 patients underwent a modified radical mastectomy and two underwent breast-conserving surgery. The majority of patients received chemotherapy and radiotherapy in the adjuvant setting and tamoxifen was the drug of choice in all patients considered as candidates for hormonal therapy. Conclusion: While most of the data presented matches that reported by other authors, some interesting differences unique to our population were observed. [ABSTRACT FROM AUTHOR]
- Published
- 2019